4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike

The article highlights defensive healthcare stocks amid concerns that the Fed could follow its September 25bp increase, which lifted the policy range to 3.75%-4.00%, with another hike as inflation remains elevated. August CPI rose 0.4% month over month and 3.4% year over year, while consumer confidence fell 6.7% to 81.9, its lowest level since April 2014. Zacks favors low-beta Abbott (0.59 beta), Corcept (0.40), Precigen (0.92) and Bausch Health (0.37), citing current-year expected earnings growth of 7.2%, over 100%, over 100%, and 16.6%, respectively, alongside improving consensus estimates.

Analysis

This is weak incremental information rather than a sector catalyst. “Low beta” is an unreliable defense designation for CORT, PGEN, and BHC: CORT and PGEN remain single-/limited-asset biotech exposures whose valuation is driven by trial, regulatory, and commercialization outcomes, while BHC’s equity sensitivity is materially governed by refinancing and leverage rather than its historical beta. A broad risk-off move could therefore expose a crowded-quality rotation without delivering the intended downside protection.

ABT is the only credible large-cap defensive expression, but its key sensitivity is not simply rates: procedure volumes, diagnostics normalization, China demand, and FX can dominate a modest change in discount rates. Higher nominal yields can also pressure medtech multiples despite resilient earnings, making XLV less clean than a quality cash-flow basket. Within healthcare, profitable diversified operators such as ABT, JNJ, and TMO should gain relative flows versus long-duration development-stage biotech if real yields rise over the next 1-3 months.

The contrarian read is that upward estimate revisions in CORT and PGEN may already reflect company-specific expectations, not macro insulation. The relevant diligence is whether revisions are backed by durable revenue/earnings changes and cash runway, rather than model resets off a low base. For BHC, the 6-18 month outcome hinges on deleveraging, asset-sale execution and debt-maturity management; a higher-for-longer rate regime raises the equity risk premium precisely when a superficial screen would label it defensive.

Falsification for a defensive-healthcare tilt: a sustained decline in real yields, benign inflation data, and easing financial conditions would favor higher-beta biotech and cyclicals instead. For individual names, exit on a negative clinical/regulatory event for CORT/PGEN, a material reduction in ABT organic-growth guidance, or any BHC refinancing that increases cash interest or pushes leverage reduction further out.

Key Decisions for Investors

• Do not chase the screen-driven CORT/PGEN move. Maintain only event-sized exposure until updated consensus models confirm revenue drivers, cash runway, and binary clinical/regulatory dates; use a 10-15% position stop or pre-defined event-risk budget over the next 1-3 months.
• Express defensiveness through a 3-6 month pair: long ABT (or XLV) versus short XBI. The trade targets continued real-yield pressure and a quality/profitability premium; reassess if 10-year real yields fall decisively or ABT cuts organic-growth guidance.
• Avoid treating BHC as a rate-defense long. Keep it on a refinancing/deleveraging watchlist; consider a tactical short versus XLV only if forthcoming debt disclosures show rising cash interest, delayed maturity actions, or leverage reduction below plan. No recommendation absent current maturity and liquidity data.
• For CORT, require evidence that estimate momentum converts into quarterly revenue and operating-margin upside before adding. A 1-2 quarter confirmation trade offers better asymmetry than buying a macro narrative; failure to meet revised earnings expectations would likely compress both estimates and multiple.
• Use the next CPI release and FOMC communication as timing gates: a hawkish surprise supports the ABT/XLV versus XBI relative trade over days to weeks, while softer core inflation and falling real yields are a signal to reduce the hedge rather than add healthcare beta.